表纸
市场调查报告书

原发性硬化性胆管炎:开发平台分析

Primary Sclerosing Cholangitis - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 246021
出版日期 内容资讯 英文 115 Pages
订单完成后即时交付
价格
Back to Top
原发性硬化性胆管炎:开发平台分析 Primary Sclerosing Cholangitis - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 115 Pages
简介

原发性硬化性胆管炎(PSC)是慢性的肝脏疾病,特征是伴随发炎的进行性胆汁滞留,及肝内·肝外的总肝胆管的纤维化等。主要的症状有腹痛和发冷,腹泻,倦怠感,发痒,体重减少等。主要的易罹病素质包含了年龄和发炎性肠道疾病等。此外主要治疗方法有抗生素和抗组织胺药物,胆汁酸粘合剂等。

本报告提供全球各国治疗原发性硬化性胆管炎(PSC)所用的开发中产品之开发情形相关分析,提供您开发中产品的最新趋势,及临床实验的各阶段产品一览,主要企业简介,主要药物概要,最新的产业趋势等调查,并将结果概述为以下内容。

目录

简介

  • 分析范围

原发性硬化性胆管炎概要

治疗药的开发

  • 原发性硬化性胆管炎开发中产品:概要
  • 原发性硬化性胆管炎开发中产品:比较分析

企业正在开发的治疗药

开发中产品概况

  • 临床阶段的产品

企业开发中的产品

治疗药的开发企业

  • Biotie Therapies Corp.
  • ChemoCentryx, Inc.
  • Dr. Falk Pharma GmbH
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Shire Plc

治疗药的评估

  • 单剂产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • BTT-1023
  • CCX-507
  • norursodeoxycholic acid
  • obeticholic acid
  • SHP-625
  • simtuzumab

最新开发平台趋势

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11059IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 11 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Primary Sclerosing Cholangitis - Overview
  • Primary Sclerosing Cholangitis - Therapeutics Development
  • Primary Sclerosing Cholangitis - Therapeutics Assessment
  • Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
  • Primary Sclerosing Cholangitis - Drug Profiles
  • Primary Sclerosing Cholangitis - Dormant Projects
  • Primary Sclerosing Cholangitis - Discontinued Products
  • Primary Sclerosing Cholangitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Nyrada Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1 2019
  • Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Primary Sclerosing Cholangitis - Dormant Projects, H1 2019
  • Primary Sclerosing Cholangitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top